162 related articles for article (PubMed ID: 17456742)
21. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
[TBL] [Abstract][Full Text] [Related]
22. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat.
Ke HZ; Qi H; Crawford DT; Chidsey-Frink KL; Simmons HA; Thompson DD
Endocrinology; 2000 Apr; 141(4):1338-44. PubMed ID: 10746637
[TBL] [Abstract][Full Text] [Related]
23. Embryo/fetal toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in rats and rabbits.
Ozolins TR; Gupta U
Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):161-70. PubMed ID: 15282737
[TBL] [Abstract][Full Text] [Related]
24. Structural basis for an unexpected mode of SERM-mediated ER antagonism.
Wu YL; Yang X; Ren Z; McDonnell DP; Norris JD; Willson TM; Greene GL
Mol Cell; 2005 May; 18(4):413-24. PubMed ID: 15893725
[TBL] [Abstract][Full Text] [Related]
25. Role of aspartate 351 in transactivation and active conformation of estrogen receptor alpha.
Kim JH; Lee MH; Kim BJ; Kim JH; Han SJ; Kim HY; Stallcup MR
J Mol Endocrinol; 2005 Dec; 35(3):449-64. PubMed ID: 16326832
[TBL] [Abstract][Full Text] [Related]
26. Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
Qin Z; Kastrati I; Chandrasena RE; Liu H; Yao P; Petukhov PA; Bolton JL; Thatcher GR
J Med Chem; 2007 May; 50(11):2682-92. PubMed ID: 17489582
[TBL] [Abstract][Full Text] [Related]
27. Targeted mutation of key residues at the start of helix 12 in the hERalpha ligand-binding domain identifies the role of hydrogen-bonding and hydrophobic interactions in the activity of the protein.
Zhao C; Abrams J; Skafar DF
J Steroid Biochem Mol Biol; 2006 Jan; 98(1):1-11. PubMed ID: 16191480
[TBL] [Abstract][Full Text] [Related]
28. Lasofoxifene (Pfizer).
Gennari L
Curr Opin Investig Drugs; 2005 Oct; 6(10):1067-78. PubMed ID: 16259229
[TBL] [Abstract][Full Text] [Related]
29. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
Gennari L
Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205
[TBL] [Abstract][Full Text] [Related]
30. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
Liu H; Lee ES; Deb Los Reyes A; Zapf JW; Jordan VC
Cancer Res; 2001 May; 61(9):3632-9. PubMed ID: 11325832
[TBL] [Abstract][Full Text] [Related]
31. Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in male rats.
Cappon GD; Horimoto M; Hurtt ME
Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):142-9. PubMed ID: 15282735
[TBL] [Abstract][Full Text] [Related]
32. Capacity of type I and II ligands to confer to estrogen receptor alpha an appropriate conformation for the recruitment of coactivators containing a LxxLL motif-Relationship with the regulation of receptor level and ERE-dependent transcription in MCF-7 cells.
Bourgoin-Voillard S; Gallo D; Laïos I; Cleeren A; Bali LE; Jacquot Y; Nonclercq D; Laurent G; Tabet JC; Leclercq G
Biochem Pharmacol; 2010 Mar; 79(5):746-57. PubMed ID: 19879249
[TBL] [Abstract][Full Text] [Related]
33. New scaffolds for the design of selective estrogen receptor modulators.
Martín-Santamaría S; Rodríguez JJ; de Pascual-Teresa S; Gordon S; Bengtsson M; Garrido-Laguna I; Rubio-Viqueira B; López-Casas PP; Hidalgo M; de Pascual-Teresa B; Ramos A
Org Biomol Chem; 2008 Oct; 6(19):3486-96. PubMed ID: 19082149
[TBL] [Abstract][Full Text] [Related]
34. Binding capacity of ER-α ligands and SERMs: comparison of the human, dog and cat.
Toniti W; Suthiyotha N; Puchadapirom P; Jenwitheesuk E
Asian Pac J Cancer Prev; 2011; 12(11):2875-9. PubMed ID: 22393957
[TBL] [Abstract][Full Text] [Related]
35. Lasofoxifene in osteoporosis and its place in therapy.
Swan VJ; Hamilton CJ; Jamal SA
Adv Ther; 2010 Dec; 27(12):917-32. PubMed ID: 21080249
[TBL] [Abstract][Full Text] [Related]
36. Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Peterson GM; Naunton M; Tichelaar LK; Gennari L
Ann Pharmacother; 2011 Apr; 45(4):499-509. PubMed ID: 21467260
[TBL] [Abstract][Full Text] [Related]
37. Structural plasticity in the oestrogen receptor ligand-binding domain.
Nettles KW; Bruning JB; Gil G; O'Neill EE; Nowak J; Guo Y; Kim Y; DeSombre ER; Dilis R; Hanson RN; Joachimiak A; Greene GL
EMBO Rep; 2007 Jun; 8(6):563-8. PubMed ID: 17468738
[TBL] [Abstract][Full Text] [Related]
38. Selective estrogen receptor modulators: the future in menopausal treatment.
Palacios S
Minerva Ginecol; 2011 Jun; 63(3):275-86. PubMed ID: 21654612
[TBL] [Abstract][Full Text] [Related]
39. Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism.
Kallen J; Lattmann R; Beerli R; Blechschmidt A; Blommers MJ; Geiser M; Ottl J; Schlaeppi JM; Strauss A; Fournier B
J Biol Chem; 2007 Aug; 282(32):23231-9. PubMed ID: 17556356
[TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor α/β-cofactor motif interactions; interplay of tyrosine 537/488 phosphorylation and LXXLL motifs.
Nguyen HD; Phan TT; Carraz M; Brunsveld L
Mol Biosyst; 2012 Oct; 8(12):3134-41. PubMed ID: 22930062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
